Literature DB >> 21112965

Risk factors for ileus in patients with schizophrenia.

Jimmi Nielsen1, Jonathan M Meyer.   

Abstract

Constipation is a known side effect of psychotropics that possess high affinity for muscarinic cholinergic receptors. In severe cases, constipation progresses to ileus and bowel ischemia, with multiple fatalities related to sepsis and perforation described in the literature, primarily among patients with schizophrenia. A historical prospective database study was performed using registry data from psychiatric and somatic hospitals, combined with the prescription database to examine associations between medications and ileus. Only cases with an ICD-10 diagnosis of schizophrenia (F20) and a concurrent diagnosis of ileus in the years 1996-2007 were included in the study. A total of 26,720 patients with schizophrenia were identified with 123 cases of ileus noted in the study period. Increasing age (OR: 1.03 CI: 1.01-1.04) and female sex (OR: 1.60 CI: 1.10-2.31) were associated with an increased risk of ileus. Treatment with clozapine (OR: 1.99 CI: 1.21-3.29), high-potency first-generation antipsychotics (OR: 1.81 CI: 1.01-3.23), tricyclic antidepressants (OR: 2.29 CI: 1.29-4.09), anticholinergics (OR: 1.48 CI: 1.00-2.19), and opioids (OR: 2.14 CI: 1.36-3.36) were associated with an increased risk of ileus. The onset of ileus occurred on average more than 3 years after the first prescription of the offending drug. Aripiprazole and amisulpride were not associated with ileus. Nine of the ileus cases (7.3%) had a fatal course. Treatment with clozapine (OR: 6.73 CI: 1.55-29.17) or anticholinergics (OR: 5.88 CI: 1.47-23.58) were associated with increased risk of fatal ileus. Patients receiving psychotropics associated with significant anticholinergic properties should undergo proper monitoring and interventions in order to minimize the burden of constipation and the risk of ileus.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21112965      PMCID: PMC3329981          DOI: 10.1093/schbul/sbq137

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  57 in total

1.  Severe bowel ischemia due to clozapine with complete remission after withdrawal.

Authors:  Covadonga Martínez Díaz-Caneja; Manuel González-Molinier; Javier Conejo Galindo; Miguel Moreno Iñiguez
Journal:  J Clin Psychopharmacol       Date:  2010-08       Impact factor: 3.153

2.  Rapidly fatal clozapine-induced intestinal obstruction without prior warning signs.

Authors:  Joey Shuk Yan Leung; Chi Chiu Lee; Wing King Lee; Patrick Po Keung Kwong
Journal:  Aust N Z J Psychiatry       Date:  2008-12       Impact factor: 5.744

3.  10-year trends in the treatment and outcomes of patients with first-episode schizophrenia.

Authors:  Jimmi Nielsen; P le Quach; C Emborg; L Foldager; C U Correll
Journal:  Acta Psychiatr Scand       Date:  2010-11       Impact factor: 6.392

4.  Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk.

Authors:  C B Pedersen; P B Mortensen
Journal:  Arch Gen Psychiatry       Date:  2001-11

5.  Determinants of poor dental care in patients with schizophrenia: a historical, prospective database study.

Authors:  Jimmi Nielsen; Povl Munk-Jørgensen; Søren Skadhede; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-06-15       Impact factor: 4.384

6.  Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.

Authors:  Julio Bobes; Celso Arango; Pedro Aranda; Rafael Carmena; Margarida Garcia-Garcia; Javier Rejas
Journal:  Schizophr Res       Date:  2006-11-21       Impact factor: 4.939

7.  Family history of psychiatric illness as a risk factor for schizoaffective disorder: a Danish register-based cohort study.

Authors:  Thomas Munk Laursen; Rodrigo Labouriau; Rasmus W Licht; Aksel Bertelsen; Trine Munk-Olsen; Preben Bo Mortensen
Journal:  Arch Gen Psychiatry       Date:  2005-08

8.  Life-threatening constipation associated with clozapine.

Authors:  Sanil Rege; Tim Lafferty
Journal:  Australas Psychiatry       Date:  2008-06       Impact factor: 1.369

9.  Antipsychotics-induced ischaemic colitis and gastrointestinal necrosis: a review of the French pharmacovigilance database.

Authors:  Hélène Peyrière; Clarisse Roux; Claire Ferard; Nathalie Deleau; Carmen Kreft-Jais; D Hillaire-Buys; Jean-Philippe Boulenger; Jean-Pierre Blayac
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-10       Impact factor: 2.890

Review 10.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

View more
  25 in total

Review 1.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.

Authors:  Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Ther Adv Drug Saf       Date:  2018-02-06

2.  Management of common adverse effects of antipsychotic medications.

Authors:  T Scott Stroup; Neil Gray
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

3.  Clozapine-induced paralytic ileus: a case report.

Authors:  Birmay Cam; Mehmet Zeki Tanircan
Journal:  Ther Adv Psychopharmacol       Date:  2014-08

Review 4.  Clozapine and Gastrointestinal Hypomotility.

Authors:  Dan Cohen
Journal:  CNS Drugs       Date:  2017-12       Impact factor: 5.749

5.  Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study.

Authors:  Marc De Hert; Liesbeth Dockx; Chiara Bernagie; Bie Peuskens; Kim Sweers; Stefan Leucht; Jan Tack; Stefan Van de Straete; Martien Wampers; Joseph Peuskens
Journal:  BMC Gastroenterol       Date:  2011-03-08       Impact factor: 3.067

Review 6.  Pharmacological treatment for antipsychotic-related constipation.

Authors:  Susanna Every-Palmer; Giles Newton-Howes; Mike J Clarke
Journal:  Cochrane Database Syst Rev       Date:  2017-01-24

Review 7.  Worldwide Differences in Regulations of Clozapine Use.

Authors:  Jimmi Nielsen; Corina Young; Petru Ifteni; Taishiro Kishimoto; Yu-Tao Xiang; Peter F J Schulte; Christoph U Correll; David Taylor
Journal:  CNS Drugs       Date:  2016-02       Impact factor: 5.749

Review 8.  Antipsychotic-Induced Constipation: A Review of the Pathogenesis, Clinical Diagnosis, and Treatment.

Authors:  Yue Xu; Nousayhah Amdanee; Xiangrong Zhang
Journal:  CNS Drugs       Date:  2021-08-24       Impact factor: 5.749

9.  Association between therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and risk of ileus: a cohort study.

Authors:  Dimitri Bennett; Shreya Davé; Motonobu Sakaguchi; Chia-Hsien Chang; Paul Dolin
Journal:  Diabetol Int       Date:  2016-03-04

10.  Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study.

Authors:  Daniel J Smith; Julie Langan; Gary McLean; Bruce Guthrie; Stewart W Mercer
Journal:  BMJ Open       Date:  2013-04-17       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.